Drugs that contain Osimertinib Mesylate
1. Tagrisso patents expiration
TAGRISSO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9732058 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(8 years from now) | |
| US11524951 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(8 years from now) | |
| US8946235 | ASTRAZENECA | 2-(2,4,5-substituted-anilino) pyrimidine compounds |
Aug, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10183020 | ASTRAZENECA | Pharmaceutical compositions comprising AZD9291 |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-176) | Apr 18, 2025 |
| Orphan Drug Exclusivity(ODE-337) | Dec 18, 2027 |
| Orphan Drug Exclusivity(ODE-102) | Nov 13, 2022 |
| New Indication(I-774) | Apr 18, 2021 |
| New Indication(I-853) | Dec 18, 2023 |
| Orphan Drug Exclusivity(ODE) | Nov 13, 2022 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2020 |
NCE-1 date: 14 November, 2019
Market Authorisation Date: 13 November, 2015
Treatment: Treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21l858r mutations; Adjuvant therapy after t...
Dosage: TABLET;ORAL
How can I launch a generic of TAGRISSO before it's drug patent expiration?
More Information on Dosage
TAGRISSO family patents
